Investment Thesis
OnKure is a clinical-stage pharmaceutical company with severe operational losses ($15.2M net loss on only $458K revenue) and no clear path to profitability. While the strong balance sheet ($192.1M cash, zero debt) provides substantial runway, the fundamental lack of revenue generation and massive cash burn (-$12.9M annually) represent significant headwinds that overshadow balance sheet strength.
Strengths
- Fortress balance sheet with $192.1M cash and zero debt, providing 14+ years of runway at current burn rate
- Exceptional liquidity position (13.78x current ratio) with minimal liabilities ($14.3M), ensuring operational flexibility
- Improving loss trajectory with net losses declining 13% YoY, suggesting operational efficiency gains or development progress
Risks
- Pharmaceutical development risk: drug candidates may fail clinical trials, regulatory approval, or market adoption, leaving cash burn unreimbursed
- Minimal revenue ($458K) with operating margin of -3409% indicates company is far from commercialization and profitability
- Accelerating cash burn risk: as clinical programs advance (Phase 2/3 trials), monthly burn rate typically increases, potentially eroding runway faster than current projections
- Dilution risk from future capital raises or employee stock compensation given lack of profits to support share buybacks
Key Metrics to Watch
- Monthly cash burn rate and runway extension/contraction
- Clinical trial progress and regulatory milestones (FDA meetings, trial enrollment, safety signals)
- Revenue growth trajectory and market adoption of any approved/commercialized products
- Operating expense trend relative to clinical development progress
- Equity dilution from financing activities or stock-based compensation
Financial Metrics
Revenue
458.0K
Net Income
-15.2M
EPS (Diluted)
$-1.11
Free Cash Flow
-12.9M
Total Assets
198.7M
Cash
192.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-3,409.4%
Net Margin
-3,309.4%
ROE
-8.2%
ROA
-7.6%
FCF Margin
-2,826.0%
Balance Sheet & Liquidity
Current Ratio
13.78x
Quick Ratio
13.78x
Debt/Equity
0.00x
Debt/Assets
7.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:02:59.669235 |
Data as of: 2026-03-31 |
Powered by Claude AI